IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 11.83 Million USD | 15.63% |
| 2022 | 10.23 Million USD | 47.64% |
| 2021 | 6.93 Million USD | -9.97% |
| 2020 | 7.7 Million USD | 237.85% |
| 2019 | 2.28 Million USD | -68.6% |
| 2018 | 7.26 Million USD | 0.96% |
| 2017 | 7.19 Million USD | 180.35% |
| 2016 | 2.56 Million USD | 65.91% |
| 2015 | 1.54 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 82.35 Thousand USD | -84.13% |
| 2007 | 518.85 Thousand USD | 207.49% |
| 2006 | 168.73 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 5.2 Million USD | -56.01% |
| 2023 Q2 | 5.38 Million USD | 0.32% |
| 2023 FY | 11.83 Million USD | 15.63% |
| 2023 Q4 | 11.83 Million USD | -22.13% |
| 2023 Q3 | 15.2 Million USD | 182.48% |
| 2023 Q1 | 5.36 Million USD | -47.6% |
| 2022 Q3 | 10.24 Million USD | -0.41% |
| 2022 Q4 | 10.23 Million USD | -0.03% |
| 2022 Q1 | 10.31 Million USD | 48.77% |
| 2022 Q2 | 10.28 Million USD | -0.32% |
| 2022 FY | 10.23 Million USD | 47.64% |
| 2021 Q2 | 8.58 Million USD | 14.94% |
| 2021 Q4 | 6.93 Million USD | -4.32% |
| 2021 FY | 6.93 Million USD | -9.97% |
| 2021 Q3 | 7.24 Million USD | -15.57% |
| 2021 Q1 | 7.46 Million USD | -3.04% |
| 2020 Q1 | 2.13 Million USD | -6.27% |
| 2020 Q2 | 6.02 Million USD | 182.08% |
| 2020 FY | 7.7 Million USD | 237.85% |
| 2020 Q3 | 6.01 Million USD | -0.25% |
| 2020 Q4 | 7.7 Million USD | 28.11% |
| 2019 FY | 2.28 Million USD | -68.6% |
| 2019 Q4 | 2.28 Million USD | -70.96% |
| 2019 Q3 | 7.85 Million USD | -1.84% |
| 2019 Q2 | 7.99 Million USD | 0.91% |
| 2019 Q1 | 7.92 Million USD | 9.17% |
| 2018 Q2 | 7.63 Million USD | 10.8% |
| 2018 Q3 | 7.67 Million USD | 0.59% |
| 2018 FY | 7.26 Million USD | 0.96% |
| 2018 Q4 | 7.26 Million USD | -5.41% |
| 2018 Q1 | 6.88 Million USD | -4.24% |
| 2017 Q1 | 2.41 Million USD | -6.04% |
| 2017 FY | 7.19 Million USD | 180.35% |
| 2017 Q4 | 7.19 Million USD | -2.16% |
| 2017 Q3 | 7.35 Million USD | 220.96% |
| 2017 Q2 | 2.29 Million USD | -4.98% |
| 2016 FY | 2.56 Million USD | 65.91% |
| 2016 Q4 | 2.56 Million USD | 2.11% |
| 2016 Q3 | 2.51 Million USD | -12.11% |
| 2016 Q2 | 2.85 Million USD | 46.04% |
| 2016 Q1 | 1.95 Million USD | 26.58% |
| 2015 Q1 | 356 Thousand USD | 0.0% |
| 2015 Q3 | 294 Thousand USD | -13.53% |
| 2015 FY | 1.54 Million USD | 0.0% |
| 2015 Q2 | 340 Thousand USD | -4.49% |
| 2015 Q4 | 1.54 Million USD | 425.85% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q3 | 93.7 Thousand USD | 8.7% |
| 2009 Q2 | 86.2 Thousand USD | 8.43% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q1 | 79.5 Thousand USD | -3.47% |
| 2009 FY | - USD | -100.0% |
| 2008 Q2 | 503.38 Thousand USD | -13.89% |
| 2008 Q4 | 82.35 Thousand USD | -12.63% |
| 2008 Q3 | 94.26 Thousand USD | -81.27% |
| 2008 Q1 | 584.55 Thousand USD | 12.66% |
| 2008 FY | 82.35 Thousand USD | -84.13% |
| 2007 Q2 | 530.91 Thousand USD | 223.23% |
| 2007 Q4 | 518.85 Thousand USD | 41.48% |
| 2007 Q1 | 164.25 Thousand USD | -2.66% |
| 2007 FY | 518.85 Thousand USD | 207.49% |
| 2007 Q3 | 366.73 Thousand USD | -30.92% |
| 2006 Q2 | 178.15 Thousand USD | 0.0% |
| 2006 Q4 | 168.73 Thousand USD | -13.44% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 168.73 Thousand USD | 0.0% |
| 2006 Q3 | 194.94 Thousand USD | 9.42% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| HST Global, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -7813.03% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -5063.308% |
| CytoDyn Inc. | 141 Thousand USD | -8296.454% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 78.711% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 36.43 USD | -32497841.257% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -3107.975% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -1112587.97% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 41.714% |
| SQZ Biotechnologies Company | 20.9 Million USD | 43.378% |
| Resverlogix Corp. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -9273.565% |
| Mesoblast Limited | 100.29 Million USD | 88.196% |
| GB Sciences, Inc. | 322 Thousand USD | -3576.708% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -7813.03% |
| Evofem Biosciences, Inc. | 8000.00 USD | -147887.5% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -523.608% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -7109.89% |
| ContraFect Corporation | 2.21 Million USD | -435.701% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -118.171% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -4356.868% |
| LadRx Corporation | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.895% |
| Biomind Labs Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -574.403% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -431.851% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -20088.602% |
| Marizyme, Inc. | 667.12 Thousand USD | -1674.619% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -51.395% |
| Zenith Capital Corp. | 4456.00 USD | -265586.715% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -7792.667% |
| Genus plc | 228.2 Million USD | 94.812% |
| Pharming Group N.V. | 166.1 Million USD | 92.873% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -214685.922% |
| IMV Inc. | 27.39 Million USD | 56.79% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -3846.333% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enzolytics Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 22.893% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -743.874% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -43.26% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -863.805% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -2034.73% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -46696.316% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -6814.092% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 592.19 Thousand USD | -1899.162% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -5054.316% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -14698.75% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 287.12 Million USD | 95.877% |
| International Stem Cell Corporation | 445 Thousand USD | -2560.449% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -45.264% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -2490.591% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -919.724% |
| PureTech Health plc | 18.25 Million USD | 35.129% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -7792.667% |
| IXICO plc | 275 Thousand USD | -4205.091% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 55.0% |
| CSL Limited | 11.23 Billion USD | 99.895% |
| Cellectis S.A. | 36.21 Million USD | 67.306% |